IMNEWRUN announced in April 2025 that Professor Seung-gu Kang from the Advanced Institute of Nanotechnology (SAINT) and the Department of Nano Engineering at Sungkyunkwan University has joined the company as Vice President and Scientific Faculty.

Professor Kang, who currently serves as an Associate Professor at SAINT, has distinguished himself in the fields of generative biology and physics-based computational biophysics. He earned his Ph.D. in Chemistry from the University of Pennsylvania under the guidance of Prof. Jeffery G. Saven, following his M.S. and B.S. degrees in Chemistry from Yonsei University. Additionally, his 13-year tenure at IBM’s Thomas J. Watson Research Center, where he led innovative research in protein design and algorithm development using noncanonical amino acids, underscores his expertise.

IMNEWRUN is set to accelerate the development of innovative antibody therapeutics based on its next-generation blood–brain barrier (BBB) penetration platform, TRANSMAB®. With extensive collaborative experience at renowned institutions such as Harvard, MGH, MIT’s Ragon Institute, and the Cleveland Clinic, Professor Kang’s appointment is expected to further bolster the company’s R&D capabilities and positively impact the domestic biotechnology sector.